Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
PAVE(Phased Avelumab combined with chemotherapy as first-line treatment for patients with
advanced small-cell lung cancer) is a Greek, investigator- initiated, single arm open- label
phase II study of Avelumab in combination with cisplatin or carboplatin/ etoposide.
The study will include an initial safety run-in, open-label, singlearm part (Part 1), and the
actual phase II study (Part 2). The total number of patients will not change (the safety
run-in patients will be included in the final total number of participants). The safety
run-in period will not alter the total study timelines, as phase II accrual will follow
immediately after the safety run-in.